(Q35198923)

7 August 2017

1 reference

title

Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease (English)

1 reference

7 August 2017

0 references

1

Mary E D Flowers

1 reference

7 August 2017

2

Paul J Martin

1 reference

7 August 2017

publication date

1 July 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

44

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

1141-1146

1 reference

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Effect of Thalidomide on the Graft versus Host Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Immunosuppression by thalidomide: implications for teratology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide as replacement for steroids in immunosuppression after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide treatment for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Thalidomide for the treatment of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

Response to thalidomide therapy in refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000079096

10.1080/1042819031000079096

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference